文献速递浆细胞疾病

卡非佐米或硼替佐米联合美法仑泼尼松治疗不适合移植的新诊断多发性骨髓瘤

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
PubMed 文献 · Blood · 2019-02-28

3期CLARION研究将不适合移植的新诊断多发性骨髓瘤患者1:1随机分配至卡非佐米-美法仑-泼尼松(KMP)或硼替佐米-美法仑-泼尼松(VMP)组,共955例。中位无进展生存期KMP组22.3个月 vs VMP组22.1个月(HR 0.906;95%CI 0.746-1.101;P=0.159),无统计学显著差异。KMP组急性肾衰竭和心力衰竭发生率高于VMP组,但≥2级周围神经病变发生率低于VMP组。

要点

  • KMP与VMP的中位PFS无统计学显著差异(22.3 vs 22.1个月;HR 0.906;P=0.159)。
  • KMP组急性肾衰竭(13.9% vs 6.2%)和心力衰竭(10.8% vs 4.3%)发生率较VMP组高至少5个百分点。
  • KMP组≥2级周围神经病变发生率低于VMP组(2.5% vs 35.1%)。

核心结论

  • CLARION研究中,KMP方案相比VMP方案未在无进展生存期上取得统计学显著差异。

研究设计与样本

  • 3期CLARION研究,将不适合移植的新诊断多发性骨髓瘤患者1:1随机分配至KMP或VMP组,治疗9个42天周期。
  • 意向治疗人群共955例:KMP组478例,VMP组477例。

主要发现

  • 中位无进展生存期KMP组22.3个月 vs VMP组22.1个月(HR 0.906;95%CI 0.746-1.101;P=0.159)。
  • 中位总生存期两组相似,均未达到(HR 1.08;95%CI 0.82-1.43)。
  • 总缓解率KMP组84.3% vs VMP组78.8%;完全缓解率KMP组25.9% vs VMP组23.1%;微小残留病阴性率KMP组15.7% vs VMP组15.5%。
  • KMP组较VMP组发生率高出≥5个百分点的任何级别不良事件:急性肾衰竭13.9% vs 6.2%,心力衰竭10.8% vs 4.3%。
  • ≥3级不良事件发生率KMP组74.7% vs VMP组76.2%;≥2级周围神经病变KMP组2.5% vs VMP组35.1%。

关键数值与推荐

  • 卡非佐米给药:第1、2、8、9、22、23、29、30天;第1周期第1、2天20 mg/m2,此后36 mg/m2。
  • 硼替佐米给药:第1、4、8、11、22、25、29、32天,1.3 mg/m2;第5-9周期省略第4、11、25、32天。
  • 美法仑9 mg/m2和泼尼松60 mg/m2在第1-4天给药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 CLARION study compared carfilzomib-melphalan-prednisone (KMP) with bortezomib-melphalan-prednisone (VMP) in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. Patients were randomized 1:1 to KMP or VMP for nine 42-day cycles (C). Patients received carfilzomib on days (D) 1, 2, 8, 9, 22, 23, 29, 30 (20 mg/m2: C1D1, C1D2; 36 mg/m2 thereafter) or bortezomib on D1, 4, 8, 11, 22, 25, 29, 32 (1.3 mg/m2; D4, 11, 25, 32 omitted for C5-9). Melphalan (9 mg/m2) and prednisone (60 mg/m2) were administered on D1-4. The primary endpoint was progression-free survival (PFS). Nine hundred fifty-five patients were randomized (intention-to-treat population: KMP, n = 478; VMP, n = 477). Median PFS was 22.3 months with KMP vs 22.1 months with VMP (hazard ratio [HR], 0.906; 95% confidence interval [CI], 0.746-1.101; P = .159). Median overall survival was similar and not reached in either group (HR, 1.08; 95% CI, 0.82-1.43). Overall response rate was 84.3% for KMP and 78.8% for VMP. Complete response rate was 25.9% for KMP and 23.1% for VMP. Minimal residual disease-negative rates were 15.7% (KMP) and 15.5% (VMP). Adverse events (AEs) of interest (any grade) occurring with a ≥5% higher patient incidence in the KMP arm were acute renal failure (13.9% [KMP] vs 6.2% [VMP]) and cardiac failure (10.8% vs 4.3%). Grade ≥3 AE rates were 74.7% (KMP) and 76.2% (VMP). Grade ≥2 peripheral neuropathy was lower for KMP vs VMP (2.5% vs 35.1%). Treatment with KMP in CLARION did not yield a statistically significant difference in PFS vs VMP. This trial was registered at www.clinicaltrials.gov as #NCT01818752.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019. PMID: 30819926. doi:10.1182/blood-2018-09-874396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。